Publications

Rather than proposing universal basic income as the solution to robots supposedly taking all our jobs, the task should be to improve federal worker adjustment assistance programs.

Rural communities face structural barriers to diagnosing Alzheimer’s early, which increases burdens on patients and caregivers while raising health-care costs. Policymakers should address the problem by expanding provider training and accelerating scalable diagnostic technologies.

The United States should use MC14 to push for a WTO that actively promotes fair market competition—not one that passively accepts non-market policies, overcapacity, and coercive distortions that are undermining the global trading system.

Despite what the apostles of artificial general intelligence warn, there is no reason to think AGI will get here anytime soon, if ever.

Seventy percent of young Koreans hold university degrees. Only 14 percent of jobs are in large firms. The most immediate concern is not jobs disappearing due to AI, but that there are too few high-quality jobs in the first place.

To protect individuals while preserving the open information ecosystem that supports innovation, policymakers should focus on outputs rather than training inputs, encourage transparency norms for autonomous AI agents, and create a safe harbor for responsible use of publicly available data.

A study of a 2010s expansion of high-speed broadband across Turkey found that that access to high-speed Internet increased formal employment and wages, with the greatest effects concentrated in telework-possible positions and among women.

Center for Data Innovation Director Daniel Castro sent a letter to Maryland Senate Finance Committee Chair Pamela G. Beidle, Vice Chair Antonio L. Hayes, and members of the committee in opposition to Senate Bill 889.

A select group of advanced, globally traded industries serves as the bedrock of U.S. technological leadership, economic power, and national security. Policymakers need to closely monitor the relative strength and vulnerability of its production capabilities.

The pharmaceutical and medicine industry has seen its productivity decline by 2.4 percent annually between 2014 and 2024, one of the worst performances among U.S. manufacturing industries.